Leukemia

Women who were treated for Hodgkin lymphoma during childhood and adolescence had similar rates of post-treatment parenthood as that of the general population.

CML patients with more comorbidities at diagnosis have significantly reduced overall survival, according to an analysis of the randomized CML-Study IV.

A new study using CML in blast crisis cells has identified existing anticancer agents that may provide benefit to patients with this difficult-to-treat disease.

Older adults with acute myeloid leukemia have a substantial health care burden and high rates of health care utilization even at the end of life.

A revised International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS) could allow for more precise staging for children and adolescents with NHL.

This session at ONS reviewed treatment options for CLL and the issues associated with bone marrow transplantation in eligible patients.

Patients with early-stage Hodgkin lymphoma who have a negative PET finding after 3 cycles of chemotherapy have a good prognosis without undergoing radiotherapy.

Researchers have found immunologic evidence that simian virus 40 (SV40) may be associated with non-Hodgkin lymphoma (NHL).

In this review we discuss adoptive cellular immunotherapies, small-molecule inhibitors, and immunomodulatory agents. We also mention other novel therapies on the horizon.

With each passing year, chemotherapy is less and less a focus of interest. Instead, the focus is on the abundance of exciting new biologic and targeted agents that are bulldozing the therapeutic landscape in the lymphomas and chronic lymphocytic leukemia.

Results from a small study suggest that treatment with interferon alpha 2a could help chronic myeloid leukemia patients discontinue imatinib treatment.

A small retrospective study of heavily pretreated patients with chronic myeloid leukemia found bosutinib to be a good option in the fourth-line setting.

Stem cell transplantation from an HLA-genoidentical sibling or an HLA-matched unrelated donor did not affect outcomes among high-risk pediatric ALL patients.

A single-arm, open-label trial in Australia found that selective early switching from imatinib to nilotinib is feasible and effective in patients with CML.

CML patients with high CIP2A levels treated with second-generation tyrosine kinase inhibitors have better outcomes than those treated with imatinib.

Results of a single-institution study found the risk for fracture among survivors of hematopoietic stem-cell transplantation increased by nearly eight times.

The next few years hold great promise, as new agents emerge and others consolidate their place on our shelves. We will be forced to rethink strategies and redefine management as a new era of immuno-oncology dawns.

Here we review monoclonal antibodies that have received FDA approval for the treatment of NHL and CLL in the last 5 years, as well as promising agents in development.

In a phase I trial, DT2219, the novel bispecific ligand-directed toxin, has shown activity against relapsed and refractory B-cell lymphoma and leukemia.

In patients with AML, post-therapy parameters including minimal residual disease and remission were found to be independent prognostic factors for outcomes.

Induction treatment for acute myeloid leukemia with amonafide L-malate/cytarabine failed to improve the rate of complete response over daunorubicin/cytarabine.

Researchers have identified patient factors linked with the discontinuation of ibrutinib therapy for reasons other than disease progression.

A new study finds that childhood cancer survivors are at risk for pituitary hormone deficiencies after radiotherapy treatment to the head.

In two phase II trials, the protein synthesis inhibitor omacetaxine offered long-term efficacy in some patients with chronic-phase and accelerated-phase CML.

Researchers have shown that axitinib could be repurposed as a treatment for CML patients resistant to standard TKIs through a certain molecular mechanism.

The FDA has expanded the approved use of ibrutinib (Imbruvica) to include patients with Waldenström macroglobulinemia, a rare type of non-Hodgkin lymphoma.

Using genome-wide association studies, researchers have identified a germline variant that is associated with intolerance to mercaptopurine in pediatric ALL.

In a recent study of pediatric ALL, minimal residual disease was able to predict patients who were at increased risk for relapse post-allogeneic stem cell transplantation.

Socioeconomic factors are reducing the use of combined-modality treatment for early-stage Hodgkin lymphoma, despite its association with increased survival.

In its Annual Report on Progress Against Cancer, ASCO has declared that the transformation in the treatment of patients with CLL is the “advance of the year.”